Recommendations made out-of-session by the PBAC March 2023 and July 2023 meetings – Changes to MS-2 Step^® PBS Listing

In an out-of-session consideration, the PBAC has recommended changes to the restriction criteria and eligible prescriber types for the PBS listings of mifepristone and misoprostol (MS-2 Step^®).       

Details of the PBAC’s recommendation can be found on the ‘Recommendations made out-of-session by the PBAC between meetings’ web page under ‘Recommendations made out-of-session by the Pharmaceutical Benefits Advisory Committee (PBAC) between its March 2023 and July 2023 meetings’.